A relative bioavailability study measuring the extent and rate of absorption of different tablet formulations of AZD1656 in Type 2 Diabetes Mellitus (T2DM) patients

Inclusion Criteria

• - Provision of signed and dated, written informed consent prior to any study specific procedures.
• - Males or females of non-childbearing potential (post-menopausal, and/or have undergone hysterectomy and/or bilateral oophorectomy or salpingectomy/ tubal ligation) aged ≥18 years. Females will be defined as post-menopausal if last menstruation period was >1 year ago and serum follicle stimulating hormone (FSH) is within the post-menopausal range, or if age >50 years and with last menstruation period >2 years ago.
• - A confirmed clinical diagnosis of T2DM for at least 1 year, treated with metformin as a single treatment or in combination with one other oral anti-diabetic (ie, DPPIV inhibitor or SU) for at least 2 months prior to screening. Doses of anti-diabetic treatment should have been stable for at least 1 month prior to screening.
• - Treatment with at least 1000mg of Metformin for 2 months and being stable on the Metformin Therapy for 1 month
• - Hb A1c >6.5% (international standard) at enrolment.
• - Body mass index (BMI) between ≥19 and ≤42 kg/m2.